je.st
news
Tag: announces merck
Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
2017-02-02 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter Non-GAAP EPS Was $0.89; Full-Year 2016 GAAP EPS Was $2.04; Full-Year Non-GAAP EPS Was $3.78 2017 Financial Outlook Expects Full-Year 2017 GAAP EPS to be Between $2.47 and $2.62; Expects Non-GAAP EPS to be Between $3.72 and $3.87, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Anticipates Full-Year 2017 Worldwide Sales to be Between $38.6 Billion and $40.1 Billion, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA Development Program U.S. Food and Drug Administration (FDA) Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score of 50 Percent or More) Without EGFR or ALK Genomic Tumor Aberrations FDA Granted Priority Review for Three Supplemental Biologics License Applications for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
financial
announces
merck
Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation
2017-01-20 22:01:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA (pembrolizumab). Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors: Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: agreement
license
patent
settlement
Merck Announces Increased Quarterly Dividend
2016-11-22 19:22:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the companys quarterly dividend to $0.47 per outstanding share of the companys common stock, up $0.01 from $0.46 per outstanding share paid last quarter. Payment will be made on Jan. 9, 2017, to stockholders of record at the close of business on Dec. 15, 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: increased
quarterly
announces
dividend
Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities
2016-11-17 15:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes Care KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the Foundation over five years, Bridging the Gap will build sustainable partnerships across sectors to support innovative approaches to diabetes treatment and management. Language: English Contact: MerckLainie Keller, 908-236-5036orJeanine Clemente, 908-236-5059 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
2016-11-13 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the companys investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »